The CEO Roundtable on Cancer brings together the nation's top executives to reduce cancer risk, enable early diagnosis, facilitate access to treatment, and hasten the discovery of effective therapies.
Founded at the request of President George H.W. Bush, we challenge corporate leaders to do something bold and venturesome about cancer within their own corporate families and beyond.
For over two decades, the CEO Roundtable on Cancer has mobilized corporate leaders to create meaningful, lasting progress in the fight against cancer.
Do something bold and venturesome about cancer within your own corporate families.
Project Data Sphere is an independent 501(c)(3) subsidiary of CEORT operating two complementary programs: an open-access data sharing platform housing 252+ de-identified clinical trials and 250,000+ patient records (NEJM), and closed-access precompetitive research projects where pharma, academia, the FDA, and technology partners collaborate on AI-driven oncology tools.
Deep learning–powered automation of RECIST 1.1 tumor assessments—reducing ~30% inter-radiologist variability.
Learn more →A novel volumetric 3D model for quantifying total tumor burden as an alternative to traditional RECIST.
Learn more →Since 2017, PDS has led the global effort to characterize, detect, and mitigate immune-related adverse events from cancer immunotherapy. Through FDA collaboration, consensus publications, and AI-powered tools, we’ve established new ICD-10-CM codes, harmonized clinical trial reporting, and created ASPIRE and STORIES—physician and patient communities advancing irAE science and safety standards worldwide.
Learn More →Launched in 2005 with NCI, START Clauses streamlined clinical trial contracting through standardized legal provisions covering intellectual property, study data, indemnification, subject injury, confidentiality, and publication rights. Developed through analysis of nearly 80 CTAs with 11 pharmaceutical companies and 14 NCI-designated cancer centers, the framework achieved 67% convergence and reduced negotiation times. Now evolving to START Clauses 2.0 with new modules for CRO management, biospecimen governance, platform trials, digital health, AI endpoints, and global data compliance.
Learn More →Conversations at the intersection of oncology, data science, and innovation — hosted by the CEO Roundtable on Cancer.
Explore the latest insights on precision oncology, AI-driven research, and breakthrough therapies. Tune in to hear from leading experts shaping the future of cancer care.
Watch on YouTube →Stay updated on the latest developments from the CEO Roundtable on Cancer and its initiatives.
The CEO Roundtable on Cancer appoints Dr. Kim Rathmell and Dr. Sunil Verma to its Life Sciences Council to strengthen oncology leadership.
Project Data Sphere’s autoRECIST initiative presented preliminary results at FDA Research Grand Rounds, advancing AI-driven tumor assessment.
Whether you're a CEO, a health leader, or an organization committed to wellness—there's a place for you in the Roundtable.